ArticleCancers2020

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.

Auris Huen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.